Skip to main content

Table 2 Patients' characteristics according to ICIs initiation within 30 days of death

From: PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort

  Control ICIs started within 30 days of death  
N° (%) N° (%)
532 (93.8) 35 (6.2)
Age    
 < 60 years old 142 (26.7) 6 (17.1) P = 0.2132
P = 0.2810
 ≥ 60 years old 390 (73.3) 29 (82.9)
 < 70 years old 300 (56.4) 23 (65.7)
 ≥ 70 years old 232 (43.6) 12 (34.3)
Gender    P = 0.7536
 Female 181 (34.0) 11 (31.4)
 Male 351 (66.0) 24 (68.6)
ECOG PS    P < 0.0001
 0—1 455 (85.5) 19 (54.3)
 ≥ 2 77 (14.5) 16 (45.7)
Primary tumor    P = 0.0172
 NSCLC 324 (60.9) 28 (80)
 Melanoma 108 (20.3) 3 (8.6)
 Renal cell carcinoma 82 (15.4) 1 (2.9)
 Others 18 (3.4) 3 (8.6)
No. of metastatic sites    P = 0.0095
 ≤ 2 208 (39.1) 6 (17.1)
 > 2 324 (60.9) 29 (82.9)
Treatment line    P = 0.1822
 First 158 (29.7) 15 (42.9)
 Second 306 (57.5) 18 (51.4)
 Further lines 68 (12.8) 2 (5.7)
  1. ICI: immune checkpoint inhibitor; ECOG-PS: eastern cooperative oncology group-performance status; NSCLC: non-small cell lung cancer